Search

2024 SEP 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Skin Diseases and Conditions - Psoriasis is the subject [...]

More than 80% of adults and adolescents with moderate-to-severe atopic dermatitis who responded to Ebglyss treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment [...]

Global Banking News-September 25, 2024-Lilly reports data showing EBGLYSS provides long-term skin clearance for atopic dermatitis (C)2024 ENPublishing - http://www.enpublishing.co.uk Pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Wednesday reported [...]

Global Banking News-September 24, 2024-Lilly's Kisunla approved in Japan for early Alzheimer's disease (C)2024 ENPublishing - http://www.enpublishing.co.uk Pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Tuesday that Kisunla (donanemab-azbt) [...]

The Ministry of Health, Labour and Welfare Japan has approved Kisunla, Eli Lilly's Alzheimer's treatment for adults with early symptomatic Alzheimer's disease, or AD, which includes people with mild cognitive [...]

2024 SEP 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced that the [...]

Deutsche Bank analyst James Shin says the Phase 2a results from Novo Nordisk's (NVO) monlunabant 'look underwhelming' and 'remove the threat of a large well-capitalized, small-molecule competitor' to Eli Lilly's [...]

Alphabet's new CFO, Anat Ashkenazi, started in July. Wall Street already has some pointers. Morgan Stanley laid out a to-do list in a note published this week for Google's new [...]

Eli Lilly and Company announced the U.S. FDA approved EBGLYSS, a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at [...]

JPMorgan raised the firm's price target on Eli Lilly to $1,100 from $1,050 and keeps an Overweight rating on the shares. The firm increased the price target into the upcoming [...]

Roche's (RHHBY) experimental obesity pill CT-996 was tied to high rates of nausea and vomiting, as well as other side effects in a small study, Bloomberg's Naomi Kresge reports. The [...]

Eli Lilly announced a $1B expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's [...]

Global Banking News-September 12, 2024-Lilly expands manufacturing footprint in Ireland (C)2024 ENPublishing - http://www.enpublishing.co.uk Pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Thursday announced a USD1bn expansion of its manufacturing [...]

Earlier, Eli Lilly and Company announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa compared to once-daily insulin degludec in adults with type 2 diabetes [...]

Eli Lilly and Company announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa compared to once-daily insulin degludec in adults with type 2 diabetes using [...]

Warren Buffett’s Berkshire Hathaway this week became the first non-tech company in the U.S. to attain a value of $1 trillion, said Yun Li in CNBC.com. The 94-year-old Buffett’s conglomerate [...]

Global Banking News-September 4, 2024-HAYA Therapeutics partners with Eli Lilly for obesity drug discovery (C)2024 ENPublishing - http://www.enpublishing.co.uk Precision medicines company HAYA Therapeutics SA announced on Wednesday that it has [...]

Qiagen (QGEN) announced it has entered into a collaboration with Eli Lilly (LLY) to support the development of a QIAstat-Dx in-vitro diagnostic, or IVD, to detect APOE genotypes which can [...]

Following a thorough review, the Medicines and Healthcare products Regulatory Agency, or MHRA, has concluded that the available evidence does not establish a causal relationship between Glucagon-Like Peptide-1, or GLP-1, [...]

U.S. health start-ups profiting from shortages of popular anti-obesity drugs are facing questions over the sustainability of their new revenue streams, Oliver Barnes of The Financial Times reports. Telehealth companies, [...]

Eli Lilly (LLY) and EVA Pharma announced that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income [...]

'Americans pay two to three times more than people in other countries for the exact same prescription drugs. It's completely unacceptable. Vice President Harris and I have taken action to [...]

Eli Lilly is cutting the price of its popular weight-loss drug to compete with counterfeit weight-loss drugs. Zepbound will be sold for $399-$549 per month, compared to a previous list [...]

Citi analyst Daniel Grosslight views Eli Lilly's (LLY) announcement that it is making Zepbound single dose vials available for self-pay patients with an on-label prescription as a 'shot across the [...]

Notable gainers among liquid option names this morning include Insulet (PODD) $194.95 +14.26, ResMed (RMD) $232.02 +6.16, Eli Lilly (LLY) $966.64 +16.11, Constellation Energy (CEG) $197.85 +2.96, and Charter (CHTR) [...]

Unusual total active option classes on open include: CAVA Group Inc (CAVA), XPeng (XPEV), Super Micro (SMCI), Paramount Global (PARA), Li Auto (LI), JD.com (JD), Eli Lilly (LLY), Opendoor Technologies [...]

Shares of Hims & Hers (HIMS) are down about 5% to $15.29 in early trading after Eli Lilly (LLY) announced Zepbound 2.5 mg and 5 mg single-dose vials are available [...]

Eli Lilly and Company announced Zepbound 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in [...]

Eli Lilly (LLY) said it is lowering the prices of the two lowest doses of Zepbound as it tries to ease supply constraints. Under the new... To see the rest [...]

After Eli Lilly announced that the company has created a new self-pay pharmacy component of LillyDirect where patients with a valid, on-label prescription from the health care provider of their [...]

Eli Lilly and Company announced Zepbound 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in [...]

Global Banking News-August 27, 2024-Eli Lilly expands Zepbound availability with discounted self-pay vials (C)2024 ENPublishing - http://www.enpublishing.co.uk Pharmaceutical company Eli Lilly and Company (NYSE: LLY) on Tuesday introduced single-dose vials [...]

2024 AUG 24 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Nutritional and Metabolic Diseases and Conditions - Type 2 [...]

Global Banking News-August 22, 2024-Oblique Therapeutics partners with Eli Lilly to advance antibody development (C)2024 ENPublishing - http://www.enpublishing.co.uk Biotechnology company Oblique Therapeutics announced on Thursday that it has entered a [...]

Shares of medical technology diabetes stocks are in the spotlight after Eli Lilly (LLY) said its weight loss drug cut the risk of developing Type 2 diabetes by 94% in [...]

Citi analyst Joanne Wuensch says medical technology diabetes stocks were pressured following Eli Lilly's (LLY) three-year, Surmount-1 results evaluating Tirzepatide, regular physical activity, and a reduced-calorie diet on prediabetes patients. [...]

Lake Street analyst Brooks O'Neil notes that Tandem Diabetes (TNDM) shares were 'slammed' yesterday in what appeared to be a reaction to news from Eli Lilly (LLY) regarding the positive [...]

Atossa Therapeutics (ATOS) and Quantum Leap Healthcare Collaborative announced the first patient has been dosed in their clinical trial evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib, a cyclin-dependent kinase [...]

Organon (OGN) announced it has expanded its agreement with Eli Lilly (LLY) to become the sole distributor and promoter for the migraine medicine Emgality in the following additional markets: Canada, [...]

Wells Fargo analyst Mohit Bansal refreshed the firm's large-cap rankings to account for some recent ratings changes and news flow. Eli Lilly (LLY) is Wells' new top pick with Vertex [...]

A 3-year-study of Zepbound and Mounjaro found the GLP-1 drugs can help prevent diabetes. The weekly injections cut the risk of developing diabetes by 94% among adults with high blood [...]

Eli Lilly announced topline results from the SURMOUNT-1 three-year study evaluating the efficacy and safety of tirzepatide once weekly for long-term weight management and delay in progression to diabetes in [...]

Global Banking News-August 20, 2024-Organon expands Emgality distribution deal with Lilly (C)2024 ENPublishing - http://www.enpublishing.co.uk Organon (NYSE:OGN), a global healthcare company with a focus on women's health, announced on Tuesday [...]

Valued at $876.3 billion, Eli Lilly & Co. https://www.barchart.com/quotes/LLY is a mega-cap pharmaceutical company that focuses on creating and distributing groundbreaking treatments for https://www.barchart.com/story/news/28071791/eli-lillys-top-glp-1-drugs-now-account-for-nearly-40-of-its-revenue-and-thats-likely-to-go-higher-in-future-quarters, cancer, immunological disorders, and neurological conditions. [...]

Evercore ISI analyst Gavin Clark-Gartner initiated coverage of Foghorn Therapeutics (FHTX) with an Outperform rating and $20 price target. Foghorn is a pioneer in the chromatin biology field, targeting proteins [...]

Guggenheim raised the firm's price target on Eli Lilly to $1,030 from $884 and keeps a Buy rating on the shares. The guidance increase again reflects Eli Lilly's overall business [...]

Berenberg analyst Kerry Holford raised the firm's price target on Eli Lilly to $1,050 from $1,000 and keeps a Buy rating on the shares. The company reported 'strong' Q2 results, [...]

BofA analysts added Duolingo (DUOL), Eli Lilly (LLY), Mid-America Apartment Communities (MAA), and McCormick (MKC) to the firm's US 1 List. The US 1 List is intended to represent BofA's [...]

Notable gainers among liquid option names this morning include Starbucks (SBUX) $93.69 +16.66, Builders First Source (BLDR) $160.75 +7.44, NVIDIA (NVDA) $113.58 +4.56, Mosaic (MOS) $28.31 +0.95, and Eli Lilly [...]

Global Banking News-August 13, 2024-Eli Lilly opens new innovation centre in Boston Seaport (C)2024 ENPublishing - http://www.enpublishing.co.uk Eli Lilly and Company (Lilly) (NYSE: LLY), a global medicine company, has officially [...]